Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies

Alfonso Fasano, Magda D'Agostino, Giacomo Caldarola, Claudio Feliciani, Celestino De Simone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Behçet's disease (BD) is a vasculitis characterized by hallmark lesions of oral and genital ulcers (Krause andWeinberger, 2008). Involvement of parenchymal central nervous system (neuro-BD) is a serious complication commonly characterized by brainstem and/or basal ganglia lesions (Al- Araji and Kidd, 2009). To date, the treatment of neuro-BD remains largely empirical, andmay not adequately control the disease (Al-Araji and Kidd, 2009). Given the well-recognized role played by tumor necrosis factor-α (TNFα) in the pathogenesis of active BD (Santos Lacomba et al., 2001), infliximab (a monoclonal antibody that binds to and neutralizes the activity of TNFα) has been adopted with favorable results in patients resistant to conventional immunosuppressive therapies and in a small placebo controlled study (Goossens et al., 2001; Arida et al., 2010).
Lingua originaleEnglish
pagine (da-a)105-107
Numero di pagine3
RivistaJournal of Neuroimmunology
Volume239
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adult
  • Antibodies, Monoclonal
  • Behcet Syndrome
  • Complementary Therapies
  • Drug Resistance, Multiple
  • Follow-Up Studies
  • Humans
  • Male
  • Neurons
  • Remission Induction
  • Time Factors

Fingerprint Entra nei temi di ricerca di 'Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies'. Insieme formano una fingerprint unica.

Cita questo